XENON XE 133
LOE ApproachingNDAINHALATIONGAS
Approved
Nov 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Xenon XE 133 is an inhaled radioactive gas approved in 1976 for pulmonary imaging and ventilation assessment. It is a diagnostic radiopharmaceutical used to evaluate lung function and detect perfusion abnormalities. The drug works by being inhaled and distributing throughout the lungs, allowing visualization via nuclear imaging.
LOE Approaching
Product approaching loss of exclusivity with low competitive pressure (30%), indicating a mature, stable diagnostic asset with limited team expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Xenon XE 133 offers minimal career growth opportunities given zero linked job postings and an LOE-approaching lifecycle stage. Roles on this product focus on maintaining market presence, regulatory compliance, and manufacturing efficiency rather than growth or innovation.
Diagnostic Product ManagerMedical Science Liaison
Worked on XENON XE 133 at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.